Lake Street analyst Frank Takkinen reiterated a Buy rating on Inspire Medical Systems (INSP – Research Report) today and set a price target of ...

The global sleep apnea implants market is expected to grow from USD 317.1 million in 2023 to USD 1,158.1 million by 2033, at ...

Awareness of sleep apnea and its relatively common and effective treatment has grown over the past three decades.

On the other hand, intermittent upper airway obstructions in OSAS during sleep would cause hypoxia with subsequent decrease in PaO 2 and increase in PaCO 2. The episodic vascular insufficiency may ...

The Food and Drug Administration (FDA) on Dec. 20 approved the obesity medication Zepbound (tirzepatide) as the first pharmaceutical treatment for moderate-to-severe obstructive sleep apnea (OSA) in ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.

Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary ...

Nyxoah's Genio implant is poised to revolutionize Obstructive Sleep Apnea treatment ... which offers a less intrusive alternative to CPAP and Inspire Therapy. Despite a high burn rate, Nyxoah ...

(Getty Images) (NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea in obese adults earlier this month. “This is a major step ...

Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s ...